

Troels Holz Borch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4503623/publications.pdf>

Version: 2024-02-01

20
papers

781
citations

687363

13
h-index

996975

15
g-index

20
all docs

20
docs citations

20
times ranked

1346
citing authors

#	ARTICLE	IF	CITATIONS
1	Bone marrow toxicity and immune reconstitution in melanoma and non-melanoma solid cancer patients after non-myeloablative conditioning with chemotherapy and checkpoint inhibition. <i>Cytotherapy</i> , 2021, 23, 724-729.	0.7	5
2	Metastatic melanoma presenting with subacute sensory neuronopathy. <i>Muscle and Nerve</i> , 2021, 64, E5-E6.	2.2	0
3	Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma. , 2021, 9, e002703.		9
4	Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. , 2021, 9, e003499.		23
5	Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma. <i>Cancers</i> , 2020, 12, 3344.	3.7	19
6	Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma. , 2020, 8, e000668.		31
7	Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer. <i>Cancers</i> , 2020, 12, 3828.	3.7	19
8	CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer. <i>Scientific Reports</i> , 2020, 10, 3914.	3.3	50
9	Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer. <i>Oncotarget</i> , 2020, 11, 2092-2105.	1.8	64
10	Differential effects of corticosteroids and anti- TNF on tumor-specific immune responses: implications for the management of irAEs. <i>International Journal of Cancer</i> , 2019, 145, 1408-1413.	5.1	36
11	Cancer immunotherapy in patients with brain metastases. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 703-711.	4.2	15
12	T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression. <i>Annals of Oncology</i> , 2018, 29, 1575-1581.	1.2	53
13	Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. <i>Oncolmmunology</i> , 2018, 7, e1502905.	4.6	80
14	Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study. <i>Cytotherapy</i> , 2017, 19, 500-513.	0.7	58
15	mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. <i>Oncolmmunology</i> , 2016, 5, e1207842.	4.6	29
16	PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. <i>Oncolmmunology</i> , 2016, 5, e1202391.	4.6	33
17	Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. <i>Clinical Cancer Research</i> , 2016, 22, 3734-3745.	7.0	234
18	Immune Monitoring Using mRNA-Transfected Dendritic Cells. <i>Methods in Molecular Biology</i> , 2016, 1428, 245-259.	0.9	3

#	ARTICLE	IF	CITATIONS
19	PD-L1-specific T cells. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 797-804.	4.2	20
20	Influence of Metronomic Cyclophosphamide and Interleukine-2 alone or Combined on Blood Regulatory T Cells in Patients with Advanced Malignant Melanoma Treated with Dendritic Cell Vaccines. <i>Journal of Clinical & Cellular Immunology</i> , 2012, 03, .	1.5	0